Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial - Nature
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial Nature
Hodgkin Lymphoma News
Beyond owl eyes - advances in pediatric and AYA Hodgkin lymphoma - St. Jude Children's Research Hospital
Beyond owl eyes - advances in pediatric and AYA Hodgkin lymphoma St. Jude Children's Research Hospital
Oncology Nurse Faces Stage 4 Lymphoma Diagnosis — and Returns Stronger - Cure Today
Oncology Nurse Faces Stage 4 Lymphoma Diagnosis — and Returns Stronger Cure Today
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore - Hartford Hospital
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore Hartford Hospital
Coexistence of Mycosis Fungoides and Hodgkin Lymphoma in a Pediatric Patient: A Report of a Rare Case - Cureus
Coexistence of Mycosis Fungoides and Hodgkin Lymphoma in a Pediatric Patient: A Report of a Rare Case Cureus
Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma - CancerNetwork
Overcoming PD-1 Resistance in Relapsed/Refractory Hodgkin Lymphoma CancerNetwork
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts - Nature
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts Nature
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom
Post-Treatment Fertility in Hodgkin Lymphoma - Hematology Advisor
Post-Treatment Fertility in Hodgkin Lymphoma Hematology Advisor
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice - Journal of Nuclear Medicine
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma: From Clinical Trials to Clinical Practice Journal of Nuclear Medicine
"Docs thought my persistent cough was asthma but it was sign of cancer" - Yahoo News Canada
"Docs thought my persistent cough was asthma but it was sign of cancer" Yahoo News Canada
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference - Health: Trusted and Empathetic Health and Wellness Information
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference Health: Trusted and Empathetic Health and Wellness Information
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? - Clinical Trials Arena
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? Clinical Trials Arena
NHS England approves breakthrough cancer therapies for rare blood cancers - National Health Executive
NHS England approves breakthrough cancer therapies for rare blood cancers National Health Executive
AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma - CancerNetwork
AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma CancerNetwork
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study - Nature
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma - UT MD Anderson
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma UT MD Anderson
Sam Neill, known for 'Jurassic Park' and 'The Piano,' dies at 78, his family says - NPR
Sam Neill, known for 'Jurassic Park' and 'The Piano,' dies at 78, his family says NPR
Hodgkin Lymphoma Develops as a Result of Arrested B Cell–Plasma Cell Transition - Inside Precision Medicine
Hodgkin Lymphoma Develops as a Result of Arrested B Cell–Plasma Cell Transition Inside Precision Medicine
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma - The ASCO Post
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma The ASCO Post
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia - Nature
Nodular lymphocyte-predominant Hodgkin lymphoma controversy and insights: a global NLPHL one working group summit report | Leukemia Nature
Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure” - Frontiers
Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure” Frontiers
Study reveals promising new therapy for non-Hodgkin lymphoma - Medical Xpress
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive
Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma - CancerNetwork
Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma CancerNetwork
BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma - CancerNetwork
BrECADD Improves PFS Vs Nivolumab/AVD in Advanced-Stage Hodgkin Lymphoma CancerNetwork
Targeted Drug Therapy for Non-Hodgkin Lymphoma - American Cancer Society
Targeted Drug Therapy for Non-Hodgkin Lymphoma American Cancer Society
Advances in lymphoma treatment therapies and clinical trials - Penn Medicine
Advances in lymphoma treatment therapies and clinical trials Penn Medicine
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic - The New York Times
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic The New York Times
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center
Hodgkin’s Lymphoma: Jonathan's Story - BMT infonet.org
Hodgkin’s Lymphoma: Jonathan's Story BMT infonet.org
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies - Frontiers
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story - Oncodaily
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma - CancerNetwork
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma CancerNetwork
Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity - Cureus
Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity Cureus
NHS Approval Of Two Rare Blood Cancer Treatments Exposes The Quiet Machinery Of Specialised Commissioning - distilledpost.com
NHS Approval Of Two Rare Blood Cancer Treatments Exposes The Quiet Machinery Of Specialised Commissioning distilledpost.com